Speaker Details

Joseph Sobanko, MD, FAAD

Joseph Sobanko, MD, FAAD

University of Pennsylvania

BIOGRAPHY

Dr. Sobanko is a distinguished dermatologic surgeon specializing in Mohs micrographic surgery, surgical reconstruction, laser surgery, and cosmetic dermatology. Currently serving as the Associate Professor and Director of Cosmetic Dermatology & Laser Surgery at The University of Pennsylvania, he passionately mentors medical students, residents, and fellows. With a prolific academic record, Dr. Sobanko has authored over 150 scientific articles, 12 textbook chapters, and co-authored the acclaimed "Safety in Office-Based Dermatologic Surgery." His groundbreaking research, supported through grants from the Dermatology Foundation and the American Society for Dermatologic Surgery, delves into the profound impact of physical appearance on patients' lives. Dr. Sobanko's diverse research interests span information asymmetry in healthcare, melanoma management, cost-effective care, and minimally invasive cosmetic procedures. Committed to global health, he extends his surgical expertise to skin cancer patients worldwide, undertaking missions in Brazil, South Africa, India, and Vietnam. Recognized as a thought leader in dermatology, Dr. Sobanko is frequently cited by prominent media outlets, including Time Magazine, Reuters, NBC Today Show, and the Los Angeles Times. His consistent excellence has earned him the title of "Top Doctor" by Philadelphia Magazine annually from 2018-2023. In 2017, he received the prestigious "Provider of the Year" award from the Clinical Practice at the University of Pennsylvania, and in 2023, he was honored with induction into the Academy of Master Clinicians, the highest clinic honor at Penn Medicine. Adding to his repertoire, Dr. Sobanko recently completed the Executive MBA Program at the Wharton School of Business, augmenting his capabilities to further contribute to his clinical, research, and global health missions.

SESSIONS

P012 Innovations in Mohs Surgery
Aug 3, 2024 9:00 AM - 12:00 PM 617

DISCLOSURES

No financial relationships exist with ineligible companies.